Iantrek
Elkins Park, US · Founded 2019 · Delaware corporation · 82 employees on LinkedIn · 7 known investors
Find your way into Iantrek
282 people in our graph share verified history with the Iantrek team — schools, employers, funds. One of them is your warm intro.
Logan Hilleunlockedknows Sean Ianchulev · together at University of California, San Francisco (overlapped)
×2knows the team · via University of California, San Francisco
knows the team · via Harvard Medical School
×3knows the team · via Harvard T.H. Chan School of Public Health
×5knows the team · via University of Rochester
Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma. Its commercialized bio-interventional solutions are used by surgeons in glaucoma patient care.
Founders & leadership
Iantrek was founded in 2019 by Tsontcho Ianchulev and Sean Ianchulev.
TI
Tsontcho IanchulevCo-founder
SI
Sean IanchulevinFounder & Chairman of the Board (CMO)Sean Ianchulev is a physician-scientist and inventor who founded Iantrek, which develops micro-interventional ophthalmic surgical technologies for glaucoma treatment. He trained at Harvard.
MH
Michael HaydinExecutive
Board
JK
FT
Farrell TysonBoard director
SB
RW
Robert WeinrebBoard director
MM
Marc-Andre MarcotteBoard director
JM
James MazzoBoard director
AC
Andrew CorleyBoard director
Investors · 7
aMoon✓ verifiedRa'anana
Visionary Ventures✓ verifiedNewport Beach · $5M – $15M
Canaan Partners✓ verifiedStamford · $500K – $20Mvia Stephen Bloch · board
Civilization Ventures Management, LlcTiburon · $1M – $10M
FemHealth VenturesShort Hills
JSD Capital, LLCNew York · $10Mvia Jordan S. Davis · inferred
US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
Reported raises · per SEC filings
Form D private placements$58.2M disclosed across 4 rounds · 2020–2025
▶$34.7MraisedAug 2025 · 21 investors · BiotechnologyRule 506(b)
▶$34.7MraisedAug 2025 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tsontcho IanchulevExecutive Officer, Director
- Todd SoneDirector
- James MazzoDirector
- Adam SzaronosExecutive Officer, Director
- Casey TanseyDirector
- Robert WeinrebDirector
- Marc-Andre MarcotteDirector
- Jeffry K. WeinhuffDirector
- Michael HaydinExecutive Officer
- Farrell TysonDirector
- Offering amount
- $42M
- Amount sold
- $34.7M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedFeb 2025 · 4 investors · BiotechnologyRule 506(b)
▶$2.8MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HaydinExecutive Officer
- Robert WeinrebDirector
- Tsontcho IanchulevExecutive Officer, Director
- Marc-Andre MarcotteDirector
- Jeffry K WeinhuffDirector
- Farrell TysonDirector
- James MazzoDirector
- Offering amount
- $5.5M
- Amount sold
- $2.8M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.4MraisedAug 2022 · 25 investors · BiotechnologyRule 506(b)
▶$15.4MraisedAug 2022 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael George Haydin, IVExecutive Officer
- James MazzoDirector
- Jeffrey K. WeinhuffDirector
- Farrell TysonDirector
- Tsontcho IanchulevExecutive Officer, Director
- Marc-Andre MarcotteDirector
- Robert WeinrebDirector
- Offering amount
- $25M
- Amount sold
- $15.4M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5.2MraisedOct 2020 · 29 investors · BiotechnologyRule 506(b)
▶$5.2MraisedOct 2020 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WeinrebDirector
- James MazzoDirector
- Jeffry K WeinhuffDirector
- Andrew CorleyDirector
- Tsontcho IanchulevExecutive Officer, Director
- Stephen BlochDirector
- Michael HaydinExecutive Officer
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Iantrek went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with Iantrek for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Iantrek do?
- Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma. Its commercialized bio-interventional solutions are used by surgeons in glaucoma patient care.
- Who founded Iantrek?
- Iantrek was founded by Tsontcho Ianchulev, Sean Ianchulev in 2019.
- Who are Iantrek's investors?
- Iantrek's investors include aMoon, Visionary Ventures, Canaan Partners, Civilization Ventures Management, Llc, FemHealth Ventures, JSD Capital, LLC, US Venture Partners.
- How much funding has Iantrek raised?
- Iantrek has disclosed $58.2M raised across 4 rounds.
- Where is Iantrek headquartered?
- Iantrek is headquartered in Elkins Park, US.